Matches in Wikidata for { <http://www.wikidata.org/entity/Q92813444> ?p ?o ?g. }
- Q92813444 description "article scientifique publié en 2020" @default.
- Q92813444 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q92813444 description "im Januar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92813444 description "scientific article published on 18 January 2020" @default.
- Q92813444 description "wetenschappelijk artikel" @default.
- Q92813444 description "наукова стаття, опублікована 18 січня 2020" @default.
- Q92813444 name "Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial" @default.
- Q92813444 name "Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial" @default.
- Q92813444 type Item @default.
- Q92813444 label "Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial" @default.
- Q92813444 label "Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial" @default.
- Q92813444 prefLabel "Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial" @default.
- Q92813444 prefLabel "Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial" @default.
- Q92813444 P1433 Q92813444-047390D0-E532-4543-A7A4-8E3A536966B3 @default.
- Q92813444 P1476 Q92813444-13DA178A-CE7E-4859-BAB8-419F85F081D8 @default.
- Q92813444 P2093 Q92813444-08A0B61A-05FB-42E3-B25B-0271D1C0635B @default.
- Q92813444 P2093 Q92813444-47578489-55A1-43C4-912B-35D67A42B5B6 @default.
- Q92813444 P2093 Q92813444-5038DE7D-22EF-4540-81F8-CA56FE332564 @default.
- Q92813444 P275 Q92813444-9171f188-ef79-4c3f-9ad4-863e254ddc57 @default.
- Q92813444 P2860 Q92813444-0476A283-B388-4770-83B5-C2618D74A292 @default.
- Q92813444 P2860 Q92813444-0704B867-1AF6-4CFA-B1B5-7988886B5A36 @default.
- Q92813444 P2860 Q92813444-10CF9860-6BFD-4D7B-956D-32996D3F9090 @default.
- Q92813444 P2860 Q92813444-11BC4F30-C223-46A8-B070-6B829F42921E @default.
- Q92813444 P2860 Q92813444-1250F9F1-6DD7-4B13-9AD8-AF484FB47544 @default.
- Q92813444 P2860 Q92813444-1CD23841-696B-4E4B-BE85-9749AB1EC87C @default.
- Q92813444 P2860 Q92813444-22710AD7-6B5E-4CF9-81D6-F9A700F95A27 @default.
- Q92813444 P2860 Q92813444-2F323B9E-80D0-47B0-A811-F4E3192E48CD @default.
- Q92813444 P2860 Q92813444-3D838D03-CF9B-4632-9FE9-D8648F0B5B3D @default.
- Q92813444 P2860 Q92813444-409715B2-B092-497F-8EE2-9C44B7AF1212 @default.
- Q92813444 P2860 Q92813444-5AA2932C-90DC-404E-84F1-29D15B968F15 @default.
- Q92813444 P2860 Q92813444-5B91F7D6-857F-4FE5-9466-D1F89F1A8342 @default.
- Q92813444 P2860 Q92813444-5F5DA666-F981-46B0-A50D-DD7B12F687E6 @default.
- Q92813444 P2860 Q92813444-638C5823-D4F4-4E35-8B40-5D89A0AA0CB9 @default.
- Q92813444 P2860 Q92813444-66AD96E0-0D0D-4CF5-9CD9-D2B07FC0FA5C @default.
- Q92813444 P2860 Q92813444-69BCF5C2-E0B9-4A42-B3E7-D273B6D616E7 @default.
- Q92813444 P2860 Q92813444-6BC007F7-4E42-44C3-A720-A82C660E0484 @default.
- Q92813444 P2860 Q92813444-8DBDC8AF-DD79-4329-A979-575F818104A8 @default.
- Q92813444 P2860 Q92813444-9F9618BD-D030-4FD6-A6AA-705FD9BAC60D @default.
- Q92813444 P2860 Q92813444-A1E19225-8122-41C0-8518-8F097E142ECB @default.
- Q92813444 P2860 Q92813444-A2066C37-3984-4051-AB5F-BD5F51981C2D @default.
- Q92813444 P2860 Q92813444-A59238F4-BFC1-4824-A3F3-41A16F202932 @default.
- Q92813444 P2860 Q92813444-AED53FF3-4267-462B-AD2A-934376BB3F7F @default.
- Q92813444 P2860 Q92813444-B9871ED8-98C5-43D4-930A-9A2C191FD887 @default.
- Q92813444 P2860 Q92813444-BB019629-EBBA-4E28-BF96-2135116B4EAD @default.
- Q92813444 P2860 Q92813444-BD11BDC5-7B61-471E-88E9-745F684B2D6C @default.
- Q92813444 P2860 Q92813444-BE715028-A9CC-43A7-A3BD-EB3B907B7526 @default.
- Q92813444 P2860 Q92813444-BE7FB269-089F-495B-B8BB-65E2457668D3 @default.
- Q92813444 P2860 Q92813444-C42CC9D3-CB6B-4A30-B71A-F3F025718645 @default.
- Q92813444 P2860 Q92813444-D6714557-74CD-480E-BFCF-5FF5ACC68FDF @default.
- Q92813444 P2860 Q92813444-DC7D9292-A01A-403E-A363-6A0781D5B4F6 @default.
- Q92813444 P2860 Q92813444-F01A0406-75D4-4148-B32A-959B76172CEA @default.
- Q92813444 P2860 Q92813444-F4DF0C81-8915-4C58-B73B-91F25906D555 @default.
- Q92813444 P2860 Q92813444-F68C8E2E-E258-435B-97A5-D1805B4D585B @default.
- Q92813444 P31 Q92813444-B1DFE38F-FC72-4A16-9329-517E2238EA43 @default.
- Q92813444 P356 Q92813444-7E462619-F3CA-4BBA-BF29-839C25983D33 @default.
- Q92813444 P433 Q92813444-BF033D6B-16CC-4037-ABF7-227458986CB2 @default.
- Q92813444 P478 Q92813444-D921E7B6-CD42-4CB0-84E4-E2E5E6EC368A @default.
- Q92813444 P50 Q92813444-935F3DD4-5782-4719-9EC7-BFDE5831EC84 @default.
- Q92813444 P50 Q92813444-C35B1385-22BB-4577-AC17-0B2E8AF480EF @default.
- Q92813444 P577 Q92813444-7D4A78B1-A05F-416C-A4E2-2179549F6099 @default.
- Q92813444 P6216 Q92813444-373cd58d-e866-46f7-b33a-4bdc95386fee @default.
- Q92813444 P698 Q92813444-49F86DE6-ED68-4D64-8EB8-6A4B0166C0E8 @default.
- Q92813444 P921 Q92813444-08D73FA1-F11F-42D7-8547-C6B150CDF4BF @default.
- Q92813444 P921 Q92813444-933E841D-F889-4840-9282-0AFED41A4FB7 @default.
- Q92813444 P921 Q92813444-C8DAA981-3330-48FA-81EF-F4F95E361E30 @default.
- Q92813444 P921 Q92813444-EE853244-2816-462D-9474-569CE9D042E7 @default.
- Q92813444 P932 Q92813444-4D1C1FF0-9BB2-4A80-A9D2-516F8A0FE80C @default.
- Q92813444 P356 JCM9010259 @default.
- Q92813444 P698 31963648 @default.
- Q92813444 P1433 Q27724774 @default.
- Q92813444 P1476 "Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial" @default.
- Q92813444 P2093 "Bong-Soo Cha" @default.
- Q92813444 P2093 "Eun Seok Kang" @default.
- Q92813444 P2093 "Yong-Ho Lee" @default.
- Q92813444 P275 Q20007257 @default.
- Q92813444 P2860 Q24625697 @default.
- Q92813444 P2860 Q28552063 @default.
- Q92813444 P2860 Q33262505 @default.
- Q92813444 P2860 Q33614337 @default.
- Q92813444 P2860 Q34161881 @default.
- Q92813444 P2860 Q34524268 @default.
- Q92813444 P2860 Q34543009 @default.
- Q92813444 P2860 Q34585893 @default.
- Q92813444 P2860 Q34673134 @default.
- Q92813444 P2860 Q35548033 @default.
- Q92813444 P2860 Q35957448 @default.
- Q92813444 P2860 Q36581133 @default.
- Q92813444 P2860 Q37482466 @default.
- Q92813444 P2860 Q38408749 @default.
- Q92813444 P2860 Q38698155 @default.
- Q92813444 P2860 Q38729780 @default.
- Q92813444 P2860 Q38751451 @default.
- Q92813444 P2860 Q38978347 @default.
- Q92813444 P2860 Q39578117 @default.
- Q92813444 P2860 Q40314659 @default.
- Q92813444 P2860 Q42270258 @default.
- Q92813444 P2860 Q44251536 @default.
- Q92813444 P2860 Q44653784 @default.
- Q92813444 P2860 Q45990556 @default.
- Q92813444 P2860 Q46575030 @default.